Source: International Congress 2018 – Management of chronic cough and respiratory muscle dysfunction
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Smith (Manchester, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), S. Birring (London, United Kingdom), M. Kitt (Kenilworth, NJ, United States of America), M. Sher (Largo, FL, United States of America), A. Tershakovec (Kenilworth, NJ, United States of America), W. Wu (Kenilworth, NJ, United States of America), Z. Xu (Kenilworth, NJ, United States of America), D. Muccino (Kenilworth, NJ, United States of America). The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.. 811

Member's Comments

No comment yet.

Related content which might interest you: Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough Source: Eur Respir J, 56 (6) 2001387; 10.1183/13993003.01387-2020 Year: 2020 Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 The effect of leukotrienes receptor antagonists on lung function, exercise tolerance and incidence of exacerbations in patients with stable, moderate COPD Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002 Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Source: ERJ Open Res, 6 (4) 00284-2020; 10.1183/23120541.00284-2020 Year: 2020 Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC) Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017 R667 retinoid agonist modulates blood glucose in COPDe patients with improved metabolic profile compared to ATRA Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Additional overall benefit to coexistent asthma and rhinitis symptoms control in patients treated with leukotriene receptor antagonist Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020 Year: 2021 PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020 Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS Source: Eur Respir J 2003; 22: 57S-64S Year: 2003 Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough Source: ERJ Open Res, 7 (3) 00269-2021; 10.1183/23120541.00269-2021 Year: 2021 Salmeterol response is not affected by beta2-adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005 Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Does chronic opioid use impact OSA diagnosis and response to treatment with CPAP? Source: Virtual Congress 2020 – Treatment of obstructive sleep apnoea and its effects Year: 2020 TRPA1 expression and characterisation in patients with chronic cough Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 A phase I inhalation study on ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015